Bayer shares on the decline: New partnership, but challenges remain - financial expert warns against entry

Bayer shares on the decline: New partnership, but challenges remain - financial expert warns against entry

According to a report by www.deraktionaer.de,

Bayer shares posted another loss on the last trading day of the week, despite the company reporting progress in women's health. Bayer has concluded a new development and licensing agreement with the American CrossBay Medical. This agreement aims to develop a new insertion device and combination with Bayer's leading hormonal intrauterine systems (IUS).

This partnership has the potential to provide women with the full range of available contraceptives. This could strengthen Bayer's portfolio. However, the company is currently struggling with various challenges. A study flop by hopeful Asundexian increases the pressure to close the emerging patent cliff through expiring patent protection. In addition, the immense net financial debt and the ongoing glyphosate case are putting a strain on Bayer's financial situation.

From a chart perspective, there are currently few arguments for entering on the long side, and new multi-year lows are conceivable. Investors will therefore continue to stay on the sidelines for now. The company must overcome these challenges to regain investor confidence in the market.